TY - JOUR
T1 - Statins and prostate cancer risk
T2 - A case-control study
AU - Shannon, Jackilen
AU - Tewoderos, Selome
AU - Garzotto, Mark
AU - Beer, Tomasz M.
AU - Derenick, Rhianna
AU - Palma, Amy
AU - Farris, Paige E.
N1 - Funding Information:
Supported in part by US Public Health Service grant 5 M01 RR000334, this paper is the result of work also supported with resources and the use of facilities at the Portland Veterans Affairs Medical Center, Portland, Oregon.
PY - 2005/8
Y1 - 2005/8
N2 - Observational studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced cancer risk. The purpose of this case-control study was to elucidate the association between statin use and prostate cancer risk. Prostate cancer cases (n = 100), recruited upon referral for prostate biopsy, and frequency age-matched, prostate-specific antigen-normal clinic controls (n = 202) were recruited from the Portland, Oregon, Veterans Affairs Medical Center. Information on any use of statins from May 1997 through August 2004 was obtained from an electronic pharmacy database. Days of use, type of statin, dose, and prescription changes were recorded. Duration and intensity were calculated for each statin type on the basis of days of use and prescribed dose. Thirty-six percent of cases and 49 percent of controls had a record of any statin use. Following adjustment for other potential risk factors, statin use was associated with a significant reduction in prostate cancer risk (odds ratio = 0.38, 95% confidence interval: 0.21, 0.69). Furthermore, in analyses stratified by Gleason score, the inverse association with statin use was maintained only among men with Gleason scores of ≥7 (odds ratio = 0.24, 95% confidence interval: 0.11, 0.53). The results of this case-control study suggest that statins may reduce the risk of total prostate cancer and, specifically, more aggressive prostate cancer.
AB - Observational studies have shown that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin) use may be associated with reduced cancer risk. The purpose of this case-control study was to elucidate the association between statin use and prostate cancer risk. Prostate cancer cases (n = 100), recruited upon referral for prostate biopsy, and frequency age-matched, prostate-specific antigen-normal clinic controls (n = 202) were recruited from the Portland, Oregon, Veterans Affairs Medical Center. Information on any use of statins from May 1997 through August 2004 was obtained from an electronic pharmacy database. Days of use, type of statin, dose, and prescription changes were recorded. Duration and intensity were calculated for each statin type on the basis of days of use and prescribed dose. Thirty-six percent of cases and 49 percent of controls had a record of any statin use. Following adjustment for other potential risk factors, statin use was associated with a significant reduction in prostate cancer risk (odds ratio = 0.38, 95% confidence interval: 0.21, 0.69). Furthermore, in analyses stratified by Gleason score, the inverse association with statin use was maintained only among men with Gleason scores of ≥7 (odds ratio = 0.24, 95% confidence interval: 0.11, 0.53). The results of this case-control study suggest that statins may reduce the risk of total prostate cancer and, specifically, more aggressive prostate cancer.
KW - Case-control studies
KW - Cholesterol
KW - Hydroxymethylglutaryl-CoA reductase inhibitors
KW - Mevalonic acid
KW - Prostate-specific antigen
KW - Prostatic neoplasms
KW - Veterans
UR - http://www.scopus.com/inward/record.url?scp=23944487796&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=23944487796&partnerID=8YFLogxK
U2 - 10.1093/aje/kwi203
DO - 10.1093/aje/kwi203
M3 - Article
C2 - 16014776
AN - SCOPUS:23944487796
SN - 0002-9262
VL - 162
SP - 318
EP - 325
JO - American journal of epidemiology
JF - American journal of epidemiology
IS - 4
ER -